Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

(2013) B. Holkova et al.   CLINICAL CANCER RESEARCH

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

(2012) E. Mahoney et al.   BLOOD

Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4

(2012) X. Huang et al.   BLOOD

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

(2012) J. P. Leonard et al.   BLOOD

The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells

(2012) Monica Pallis et al.   BRITISH JOURNAL OF HAEMATOLOGY

CDK1 Regulates Mediator of DNA Damage Checkpoint 1 during Mitotic DNA Damage

(2012) B. Yu et al.   CANCER RESEARCH

CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies

(2012) Shuang Chen et al.   CANCER RESEARCH

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

(2012) J. J. Luke et al.   CLINICAL CANCER RESEARCH

Cyclin-Dependent Kinase 7/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor   and Bcr-Abl Oncogene Addiction in Malignant Hematologic Cells

(2012) Y. Wu et al.   CLINICAL CANCER RESEARCH

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

(2012) S. P. Glaser et al.   GENES & DEVELOPMENT

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

(2012) J. E. Karp et al.   HAEMATOLOGICA

Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα

(2012) Hanna S. Radomska et al.   JOURNAL OF CLINICAL INVESTIGATION

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

(2012) Patrick J. Roberts et al.   JNCI-Journal of the National Cancer Institute

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells

(2012) A J Johnson et al.   LEUKEMIA

Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis

(2012) Jan Molinsky et al.   LEUKEMIA & LYMPHOMA

P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines

(2012) Nitesh P Shirsath et al.   Molecular Cancer

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program

(2012) Richard Gorlick et al.   PEDIATRIC BLOOD & CANCER

Characterization of Cyclin E Expression in Multiple Myeloma and Its Functional Role in Seliciclib-Induced Apoptotic Cell Death

(2012) Liat Josefsberg Ben-Yehoshua et al.   PLoS One

Chemical Genetics Reveals a Specific Requirement for Cdk2 Activity in the DNA Damage Response and Identifies Nbs1 as a Cdk2 Substrate in Human Cells

(2012) Lara Wohlbold et al.   PLoS Genetics

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

(2011) J. E. Karp et al.   BLOOD

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications

(2011) Douglas W. McMillin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked

(2011) Simon F. Scrace et al.   CELL CYCLE

The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD

(2011) Lequn Li et al.   CELL CYCLE

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

(2011) B. Holkova et al.   CLINICAL CANCER RESEARCH

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

(2011) K C Goh et al.   LEUKEMIA

The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine

(2011) E Walsby et al.   LEUKEMIA

Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia

(2011) Jeffrey A. Jones et al.   LEUKEMIA & LYMPHOMA

Flavopiridol inducesBCL-2expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia

(2011) Dwella M. Nelson et al.   LEUKEMIA & LYMPHOMA

Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription

(2011) Sonal M. Manohar et al.   LEUKEMIA RESEARCH

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

(2011) Neil Johnson et al.   NATURE MEDICINE

Responses in Mantle Cell Lymphoma Cells to SNS-032 Depend on the Biological Context of Each Cell Line

(2010) R. Chen et al.   CANCER RESEARCH

Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors

(2010) Neil Johnson et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias

(2010) W. Blum et al.   HAEMATOLOGICA

Whether to target single or multiple CDKs for therapy? That is the question

(2010) Józefa Węsierska-Gądek et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

(2010) Wei-Gang Tong et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells

(2010) U Kruse et al.   LEUKEMIA

AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples

(2010) Matthew S. Squires et al.   MOLECULAR CANCER THERAPEUTICS

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

(2010) David Parry et al.   MOLECULAR CANCER THERAPEUTICS

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition

(2010) L Santo et al.   ONCOGENE

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

(2009) Rong Chen et al.   BLOOD

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

(2009) Andrew Conroy et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

(2009) Thomas S. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Flavopiridol, Fludarabine, and Rituximab in Mantle Cell Lymphoma and Indolent B-Cell Lymphoproliferative Disorders

(2009) Thomas S. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

(2009) N Raje et al.   LEUKEMIA

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

(2009) Judith E. Karp et al.   LEUKEMIA RESEARCH

Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage

(2009) Neil Johnson et al.   MOLECULAR CELL

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

(2008) M. A. Phelps et al.   BLOOD

A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model

(2008) E. Menu et al.   CANCER RESEARCH

CDK targets Sae2 to control DNA-end resection and homologous recombination

(2008) Pablo Huertas et al.   NATURE